Skip to main content
. 2016 Jul 28;7(35):56889–56903. doi: 10.18632/oncotarget.10872

Figure 2. MEK1/2 inhibitor U0126 reduced MMP-9 expression and activity and diminished migration and invasion in ES cell lines.

Figure 2

A. Representative blots of MEK1/2 and ERK1/2, either total or phosphorylated, in A673 and TC71 cell lines treated with vehicle (DMSO) or 20 μM U0126. Quantification of the phosphorylated vs. total ratios is shown below the blot. B. Semi-quantitative RT-PCR and corresponding quantifications showing MMP-9/β-Actin ratio in A673 and TC71 cell lines treated with vehicle (DMSO) or 20 μM U0126. C. Zymogram and corresponding quantification of the MMP-9 gelatinase activity in A673 and TC71 cell lines treated with vehicle (DMSO) or 20 μM U0126. D. Quantification of the transwell migratory capacity of A673 and TC71 treated cells (U0126) regarding their controls (DMSO). E. Quantification of the matrigel-coated transwell invasive capacity of A673 and TC71 treated cells (U0126) regarding their controls (DMSO). Statistical significance was achieved by the Student's t test: *p≤0.05 **p≤0.001 ***p≤0.0001.